- Aktuellste Pressemitteilung
- Newsroom
- Media Monitor
|
ARTES Biotechnology issued New Patent in Australia for VLP Technology
ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce...
|
|
Strategic cooperation between ARTES Biotechnology and PAC
Artes and PAC join forces and combine their technologies and know-how. ARTES Biotechnology specializes in recombinant protein production, process development in...
|
|
ARTES Announces a Strategic Collaboration Deal for Vaccine Development
ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for...
|
|
ARTES Steps Further Into the Vaccine Business by Acquiring Anavax
ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP...
|
|
Injectable Sustained Release Formulations of Therapeutic Proteins
Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation...
|
|
Erfolgreiche Zusammenarbeit zwischen ARTES und Rhein Minapharm wird fortgeführt
ARTES Biotechnology GmbH, Spezialist für die Entwicklung rekombinanter Proteine und Prozesse in Hefen, und Rhein Minapharm Biogenetics, eine Tochterfirma von Minapharm...
|
|
ARTES and Rhein Minapharm continue their successful product development collaboration
ARTES Biotechnology, specialized in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary...
|
|
Exclusive Cooperation between ARTES and the Ukrainian National Academy of Sciences
ARTES announced today that it has signed an exclusive Marketing Agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. Matter...
|
|
ARTES enters into a partnership with Henkel in a 3-year research program
ARTES Biotechnology GmbH today announces the collaboration with Henkel in a joint three years research program that is granted by the German national BMBF (German...
|
|
ARTES startet dreijährige Forschungskooperation mit Henkel
ARTES Biotechnology GmbH gab heute ihre Zusammenarbeit mit Henkel im Rahmen eines dreijährigen Forschungsvorhabens bekannt. Das Projekt wird mit Mitteln des BMBF...
|
|
ARTES Biotechnology und m2p-labs vereinbaren enge Zusammenarbeit bei Screening und Medienoptimierung und bieten exklusiv die Kombination ihrer Technologien an
ARTES Biotechnology GmbH (Langenfeld) und m2p-labs GmbH (Aachen) kündigen heute den Beginn einer langfristigen Zusammenarbeit in den Bereichen Screening und Medienoptimierung...
|
|
ARTES Biotechnology and m2p-labs join forces in clone screening and media optimization and offer an exclusive technology combination
ARTES Biotechnology GmbH (Langenfeld) and m2p-labs GmbH (Aachen) announced today the start of a long-term collaboration in clone screening and media optimisation....
|
ARTES and Minapharm sign long-term strategic development agreement
ARTES Biotechnology, which is specialized in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm...
|
|
Exklusive Zusammenarbeit ARTES und IPK
Die neuen Räumlichkeiten der Artes Biotechnology GmbH in Langenfeld beflügeln offenbar auch den geschäftlichen Eifer. Konnte Artes in jüngster Vergangenheit bereits...
|
|
Wichtiger Schritt für Artes
„Wir freuen uns darauf, in einem internationalen Konsortium mitarbeiten zu können“, so Frau Dr. Melanie Dröttboom, zuständig für das Business Development der Artes...
Elisabeth-Selbert-Str. 9
D - 40764 Langenfeld
http://www.artes-biotechnology.com
